CHPA Featured FDA Leadership, Industry Experts During Virtual Regulatory Conference

Valisure’s CEO, David Light, was invited to participate in The Consumer Healthcare Products Association (CHPA) 2021 Regulatory, Scientific & Quality (RSQ) Conference virtually from Thursday, September 9, through Friday, September 10.

CHPA’s annual event brought together highly respected experts to discuss timely regulatory, scientific, legal, and product quality topics affecting the consumer healthcare products industry. After a year of unprecedented change in healthcare, this year’s program will explore the evolving self-care landscape, including changes that are here to stay and those that lie ahead.

The RSQ agenda offered something for everyone with critical legal, regulatory and scientific, and product quality sessions over two days. Hear from FDA, USP, industry, and academia on some of the timeliest topics affecting the consumer healthcare marketplace.

‍Agenda highlights include:

• FDA/USP Leadership Panel Discussion - Theresa Michele, M.D., Director, Office of Nonprescription Drugs, Office of New Drugs, CDER, FDA, Donald D. Ashley, J.D., Director, Office of Compliance, CDER, FDA, and Jaap Venema, Ph.D., Executive Vice President & Chief Science Officer, The United States Pharmacopeial Convention, Inc
• The Consumerization of Health Care - John Whyte, M.D., Chief Medical Officer, WebMD
• DSHEA 2.0 - Liz Richardson, Project Director, Pew Charitable Trusts; Diane McEnroe, J.D., Partner, Sidley Austin, LLP
• CBD – Regulatory, Legislative, and Scientific Insights - Duffy MacKay, N.D., Senior Vice President, Scientific & Regulatory Affairs, CV Sciences, Inc.; Pete Meachum, Senior Director Government Affairs, Chronos Group; Rend Al-Mondhiry, J.D., Partner, Amin Talati Wasserman
• Considerations for the Future of Rx-to-OTC Switches - Bernie Simone, Vice President of Client Strategy and Rx-to-OTC Switch, Pinney Associates; Clark Richardson, MPH, President & CEO, PEGUS Research, Inc.; Mary Alice Lawless, Founder and Chief Client Officer, Biograph Inc.; Francis E. Becker, M.D., FACP, Director, Division of Nonprescription Drugs II, Office of Nonprescription Drugs, FDA
• Innovation Opportunities in Consumer Self-Care - Sonja Fulmer, Ph.D., Assistant Director for Digital Health Policy, CDRH, FDA, Jenna Phillips, MSc., Principal Consultant, PA Consulting
• Impurities - David Light, CEO of Valisure; Amy L. Roe, Principal Scientist, The Procter & Gamble Company; Antonio Hernandez-Cardoso, Principal Scientist, USP

CHPA Featured FDA Leadership, Industry Experts During Virtual Regulatory Conference

Valisure’s CEO, David Light, was invited to participate in The Consumer Healthcare Products Association (CHPA) 2021 Regulatory, Scientific & Quality (RSQ) Conference virtually from Thursday, September 9, through Friday, September 10.

CHPA’s annual event brought together highly respected experts to discuss timely regulatory, scientific, legal, and product quality topics affecting the consumer healthcare products industry. After a year of unprecedented change in healthcare, this year’s program will explore the evolving self-care landscape, including changes that are here to stay and those that lie ahead.

The RSQ agenda offered something for everyone with critical legal, regulatory and scientific, and product quality sessions over two days. Hear from FDA, USP, industry, and academia on some of the timeliest topics affecting the consumer healthcare marketplace.

‍Agenda highlights include:

• FDA/USP Leadership Panel Discussion - Theresa Michele, M.D., Director, Office of Nonprescription Drugs, Office of New Drugs, CDER, FDA, Donald D. Ashley, J.D., Director, Office of Compliance, CDER, FDA, and Jaap Venema, Ph.D., Executive Vice President & Chief Science Officer, The United States Pharmacopeial Convention, Inc
• The Consumerization of Health Care - John Whyte, M.D., Chief Medical Officer, WebMD
• DSHEA 2.0 - Liz Richardson, Project Director, Pew Charitable Trusts; Diane McEnroe, J.D., Partner, Sidley Austin, LLP
• CBD – Regulatory, Legislative, and Scientific Insights - Duffy MacKay, N.D., Senior Vice President, Scientific & Regulatory Affairs, CV Sciences, Inc.; Pete Meachum, Senior Director Government Affairs, Chronos Group; Rend Al-Mondhiry, J.D., Partner, Amin Talati Wasserman
• Considerations for the Future of Rx-to-OTC Switches - Bernie Simone, Vice President of Client Strategy and Rx-to-OTC Switch, Pinney Associates; Clark Richardson, MPH, President & CEO, PEGUS Research, Inc.; Mary Alice Lawless, Founder and Chief Client Officer, Biograph Inc.; Francis E. Becker, M.D., FACP, Director, Division of Nonprescription Drugs II, Office of Nonprescription Drugs, FDA
• Innovation Opportunities in Consumer Self-Care - Sonja Fulmer, Ph.D., Assistant Director for Digital Health Policy, CDRH, FDA, Jenna Phillips, MSc., Principal Consultant, PA Consulting
• Impurities - David Light, CEO of Valisure; Amy L. Roe, Principal Scientist, The Procter & Gamble Company; Antonio Hernandez-Cardoso, Principal Scientist, USP